Diversa Awarded Two Biodefense Contracts Totaling $4.8 Million
Under the RAbBC program Diversa has been applying its proprietary high-throughput proteomics and antibody optimization technologies to identify important protein targets for new vaccines and antibody therapies and to create optimized antibodies to detect and eliminate anthrax infections.
Under the EBAD program Diversa has been working in collaboration with Agentase LLC and Life Science Research Israel Ltd. (LSRI) to develop an environmentally benign, enzyme-based system that is capable of decontaminating a broad spectrum of both chemical and biological agents. Product applications of any successfully developed system potentially include decontaminating sprays, solutions, foams, wound dressings, fabrics, and protective clothing.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous